anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The aim of the present study was to compare the therapeutic effects of activated platelet-rich plasma (PRP) prepared from elderly individuals and young adults to treat pressure ulcers (PUs), and to accumulate a theoretical basis for allogeneic PRP treatment of PUs in elderly patients.
MATERIALS AND METHODS: Whole blood was extracted from elderly individuals aged >65 y and young adult volunteers for PRP preparation, and platelet concentrations in whole blood and PRP were compared. Growth factors released from activated PRP were assayed using the enzyme-linked immunosorbent assay. C57BL/6 mice were divided into three groups: the control saline, elderly-PRP (Group A), and young adult-PRP (Group B). Ischemia-reperfusion injury-induced PUs were established on the backs of mice. PUs were photographed on days 0, 5, and 10 to assess their sizes. Specimens were collected on day 10 and subjected to hematoxylin and eosin and Masson's staining. Immunohistochemical staining for CD31 was conducted to evaluate vascular formation, and cell invasion was assessed using a Transwell assay. The action of PRP on transforming growth factor-beta (TGF-β)-dependent fibroblast activity and epithelial-mesenchymal transition was analyzed using immunofluorescence and Western blotting in vitro.
RESULTS: The platelet concentrations in whole blood and PRP of young adults were significantly higher than that in elderly individuals. The two PRP treatment groups had similar platelet enrichment coefficients of PRP. After activation, PRP from young adults produced significantly higher levels of platelet-derived growth factor, TGF-β, and vascular endothelial growth factor than PRP from elderly individuals (P < 0.05). The concentrations of platelet-derived growth factor, TGF-β, and vascular endothelial growth factor were positively correlated with the platelet concentrations in whole blood and PRP. The effects of PRP in regulating the expressions of TGF-β, α-smooth muscle actin, vimentin, and E-cadherin were observed in vivo and in vitro. The two PRP treatment groups exhibited better wound healing than the control group, as evidenced by more re-epithelialization, higher collagen content, skin fibrosis, and more blood vessel formation over time. Group B exhibited better wound healing than Group A (P < 0.05).
CONCLUSION: PRP exhibits potent wound healing ability in PU therapy, and PRP from young adults is seemingly superior to that from elderly individuals because of a higher concentration of platelets and increased production of growth factors.
Patients with a history of traumatic brain injury (TBI) are at elevated risk for Alzheimer's disease and related dementias (ADRD). Improvements in TBI treatment may mitigate this risk. The treatment of TBI, especially for those with chronic neuropsychiatric sequelae, is moving toward multi-modal approaches that include non-pharmacological interventions such as exercise and cognitive enrichment. Complex motor activities, which combine physical and cognitive demands, have been shown to have well established neurocognitive benefits. However, there are a lack of cognitive enhancing interventions that utilize these complex motor activities. Many adults with history of TBI face significant barriers to engaging in physical activity which limit the adults' ability to participate in many neurocognitive interventions. This study seeks to address the need for novel TBI interventions optimized for adults with history of TBI by determining the effectiveness of an immersive computer game designed to integrating complex cognitive-motor interventions. During this proposed 12-month study involving patients with history of TBI (n=66) the investigators will examine cognition, independent function, mood and ADRD related brain biomarkers after 12 weeks of a randomized intervention, as well as 9 months post-intervention to assess for durability of any benefits. The investigators hypothesize that complex motor activities will improve cognitive health in adults with a history of TBI and that promising results would have implications for early intervention for those at risk for Mild Cognitive Impairment and ADRD.
<P>PROBLEM TO BE SOLVED: To stabilize a vitamin B1 compound in a preparation and improve the collapsibility of the solid preparation containing a glucosaminoglucan such as chondroitin sulfate.  <P>SOLUTION: The subject preparation containing the vitamin B1 compound is allowed to contain an amino sugar (glucosamine, or the like) to stabilize the vitamin B1 compound. The amount of the amino sugar used is an amount effective for stabilizing the vitamin B1 compound, such as ≥0.1 pt. wt. per pt. wt. of the vitamin B1 compound. When the amino sugar is compounded, the collapsibility of the solid preparation containing the glucosaminoglucan (hyaluronic acid, chondroitin or their salts) can be improved. The amount of the amino sugar used is ≥0.1 pt. wt. per pt. wt. of the glucosaminoglucan. Even when the pH of the solid preparation is changed, the solid preparation can prevent the formation of glucosaminoglucan gel lump to improve the collapsibility.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Accumulating evidence shows that renal fibrosis plays a key role in the development of hypertensive nephropathy (HTN). Therefore, a better understanding of the underlying mechanism of renal fibrosis regulation in HTN would be critical for designing rational strategies for therapeutic interventions. In this study, we revealed that GPR97, a novel identified adhesion G coupled receptor, plays an important role in the regulation of Wnt/β-catenin signaling, which is the crucial driver of renal fibrosis in HTN. First, we identified that the expression of GPR97 correlated with the β-catenin expression in renal biopsy from patients with HTN. Moreover, we found that GPR97 deficiency inhibited Wnt/β-catenin signaling in mice with HTN, as evidenced by the reduction of β-catenin expression and downstream target proteins, including MMP7 and Fibronectin. Mechanistically, we found that GPR97 could directly bind with Wnt1 in cultured tubular cells and TGF-β1 treatment enhanced the binding ability of GPR97 and Wnt1. In addition, the gene silencing of GPR97 could decrease the Wnt1-induced fibrotic phenotype of tubular cells and inflammatory responses, suggesting that the binding of GPR97 and Wnt1 promoted Wnt/β-catenin signaling. Collectively, our studies reveal that GPR97 is a regulator of Wnt/β-catenin signaling in HTN, and targeting GPR97 may be a novel therapeutic strategy for HTN treatment.
A method for laser revascularizing osteotrepanation (LAROT) in the treatment of tissue ischemia of the lower extremities comprises the access to a. epigastrica inferior, its catheterization and day and night administration of vascular and antibacterial preparations through the catheter. In parallel, within 20-25 days regional medical therapy is carried out, which comprises the infusion of nitric oxide donor (tivortin - 100 ml/day), angioprotectors - Actovegin (160 mg), antiplatelet agents - dipyridamol 0.5% (2 ml), nicotinic acid 1% (5 ml), lidocaine 2% (4 ml), magnesium sulfate 25% (10 ml), heparin (5000 IU), alprostan 100 µg directly through a catheter a.epigastrica inferior and further a. iliaca ext. into a. femoralis using infusion pumps day and night at the rate of 10-15 ml/hour. The irradiation course of arterial blood through catheterized a.epigastrica inferior with low-energy lasers of red (wavelength 632.8 nm, power 5 mW, the exposure 20-25 min.), infrared (wavelength 850 nm, 5 mW, the exposure 20-25 min.) and UV spectrum with the wavelength 360 nm, power 8.5 mW, the exposure 20-25 min.) using quartz-polymer monofilaments with fiber diameter of 0.4- and length of 30-. Also on 3-4 day of said therapeutic manipulations the tibial percutaneous laser revascularizing osteotrepanation (LAROT) is carried out for what the skin puncture is performed under spinal anesthesia as well as puncture of deep tissues up to the periosteum along the lateral surfaces of the tibia from 4-5 positions on each side at a distance of 2-, the monofilament LED is introduced into puncture needle having diameter and destruction of bone tissue is carried out as a tunnel with high-intensity diode laser with wavelength of 940 nm, in the modulated mode, 50:10, power of 28-32 Wt. The level of osteotrepanation openings on both sides is alternated for prevention of fractures in the postoperative period, and after removal of the monofilament LED the same punction needle in introduced in formed tunnel, which is introduced into the bone with the helical coil to 1.0-, mechanically removing carbonized tissue and expanding osteotrepanation opening, which stimulates the formation of collateral circulation of the soft tissues at the expense of the bone vessels.
IgA nephropathy (IgAN) represents the most prevalent form of primary glomerulonephritis, and, on a global scale, it ranks among the leading culprits behind end-stage kidney disease (ESKD). Presently, the primary strategy for managing IgAN revolves around optimizing blood pressure and mitigating proteinuria. This is achieved through the utilization of renin-angiotensin system (RAS) inhibitors, namely, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). As outlined by the KDIGO guidelines, individuals who continue to show a persistent high risk of progressive ESKD, even with comprehensive supportive care, are candidates for glucocorticoid therapy. Despite these therapies, some patients have a disease refractory to treatment, defined as individuals that present a 24 h urinary protein persistently >1 g after at least two rounds of regular steroids (methylprednisolone or prednisone) and/or immunosuppressant therapy (e.g., mycophenolate mofetil), or who do not tolerate regular steroids and/or immunosuppressant therapy. The aim of this Systematic Review is to revise the current literature, using the biomedical database PubMed, to investigate possible therapeutic strategies, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, fecal microbiota transplantation, as well as blockade of complement components.
Parkinson's disease is a progressive neurodegenerative disorder that is caused by degeneration of dopaminergic neuron in the substantia nigra. Most commonly used drug, levodopa can improve the dopamine level in brain but levodapa causes hyperhomocysteinmia as a result increse neurotoxicity,oxidative stress and motor fluctuations and dyskinesia in many patients. Folic acid has been reduced homocystein level in levodopa treated Parkinson's disease on animal model and also reduced Levodopa induced dyskinesia without compromising the motor benefits of Levodopa. Therefore, the present study is to attempt to improve the sign symptoms of Parkinson's disease by giving folic acid along with Levodopa.

This study is a Randomized, Double-Blind, Placebo-Controlled Trial and conducting at Department of Pharmacology, BSMMU in collaboration with Department of Neurology, BSMMU. A total of 60 patients suffering from Parkinson's disease is selected according to inclusion and exclusion criteria. The diagnosis of the patients suffering from Parkinson's disease will be performed by a neurologist at movement disorder clinic of department of Neurology, BSMMU. Patients will undergo MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) to assess the severity of the disease. The patients will be randomly allocated into two arms: control and intervention. Patients in intervention arm consisted of 30 patients who will receive levodopa plus folic acid orally for 8 weeks. On the other hand, control arm consisted of 30 patients who will receive levodopa plus placebo for 8 weeks. The severity of Parkinson's disease will be assessed 8 weeks follow up.
While R-CHOP has improved survival and is considered standard of care for patients with DLBCL, the toxicities associated with R-CHOP are substantial in the elderly population. This is one of several reasons the outcome of older patients is worse than the corresponding younger patients. Bendamustine is an alkylating agent which causes intra- and inter-strand cross-links between DNA bases. Ofatumumab is a fully human anti-CD 20 antibody well tolerated by elderly patients. Ofatumumab targets a novel epitope of the CD20 molecule on B cells and remains on the cell surface twice as long as rituximab. The combination of both agents allows for a potentially efficacious, less toxic regimen.
PURPOSE:To provide the titled drug preparation coated its surface with a hardened oil, storable under high temperature and humidity conditions without causing the adhesion of capsules with each other, resistant to change of property with time irrespective of the environmental condition and having improved workability is drug preparation, storability and adhesivity with other drugs to be compounded. CONSTITUTION:The objective capsule is surface-coated with a hardened oil. The hardened oil is solid at normal temperature and is e.g. hardened castor oil, hardened rapeseed oil, hardened cottonseed oil, hardened soybean oil, etc., or their mixture. The coating can be carried out e.g. by scattering fine powder of a hardened oil to a soft capsule agent loaded in a coating pan under rolling or spraying a soft capsule agent with a solution produce by dissolving a hardened oil in an organic solvent capable of dissolving the hardened oil. The amount of the hardened oil applied to the titled agent is preferably >=0.002pts.wt. per 100pts.wt. of the skin of the soft capsule. The hardened oil may be compounded with other agent (e.g. beeswax).
Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. A method includes receiving data representing measurements acquired by seismic sensors in response to energy that is produced by shots of a seismic source. The energy that is produced by the seismic source for each shot includes a plurality of discrete frequencies of discrete frequency bands that are within a frequency range of interest and are separated by at least one excluded frequency or frequency band. The data may be processed to determine at least one characteristic of a geologic structure.
We recruit patients with type 2 diabetes who need to be isolated due to the COVID-19 epidemic, Our study will include young and middle-aged obese patients. The lockdown period is 21 days. The patients will be randomly divided into two groups with a total follow-up time of 6 months. One group is the telemedicine intervention group, and the other group is the routine follow-up control group. The intervention group used the hospital telemedicine management system to upload blood glucose values (fasting and 2h after three meals), food intake of three meals, and exercise volume (Data collection frequency: first three months, 4 times/week; 4-6 Month, 2 times/week).Doctors will collect data from hospital telemedicine management system to guide patients on diets, exercise, and medication adjustments. The control group will be followed up by telephone/outpatient clinic every 1 week. (only telephone follow-up will be conducted during the lockdown period) Then doctors will collect their blood glucose values.(fasting and 2h after three meals) Based on the data collected, The doctors will provide lifestyle guidance to the patients on the telephone or face to face. The clinical data of the two groups of patients will be collected at baseline, 22 days, 3 months, and 6 months respectively. (HbA1c, fasting blood glucose(FBG), blood glucose 2 hours after breakfast, blood pressure, Body Mass Index(BMI), waist-to-hip ratio, total cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), Blood Urea Nitrogen(BUN), serum creatinine(Scr), e-GFR, Self-rating Depression Scale, frequency of hypoglycemia，and Cost effectiveness) The clinical data will be statistically analyzed.
A new anti-vascular endothelial growth factor agent, brolucizumab, was approved by the United States Food and Drug Administration in 2019. We evaluated whether brolucizumab reduces the treatment burden of neovascular age-related macular degeneration (nAMD) after switching by examining 1-year treatment outcomes in a real-world setting. This retrospective single-institution study included 107 consecutive eyes with nAMD treated with brolucizumab. Among these eyes, 30 with treatment-naïve nAMD and 77 treated with other anti-VEGF agents for more than a year were included. All eyes were managed using a treat and extend (TAE) or modified TAE regimen. The last injection intervals at 52 weeks were 12.9 and 12.1 weeks in the treatment-naïve and switch therapy groups, respectively. Among switch therapy group patients whose pre-switch injection intervals were shorter than 120 days (n = 62 eyes), the injection interval was significantly longer after the switch than before, with a mean difference of 2.7 weeks (P < 0.0001). Intraocular inflammation events occurred in 2 and 7 treatment-naïve and switch therapy patients, respectively. In conclusion, brolucizumab might reduce the treatment burden in patients who required the injection of other anti-VEGF agents with a 120-day interval or shorter, despite a relatively high discontinuation rate due to intraocular inflammation.
Non - agglutinating or non - agglutinable aqueous suspensions of animal tissue cells are prepared by dispersing fresh cellular material in the presence of small amounts of alcohols containing more than six carbon atoms, e.g. octyl alcohol or benzyl alcohol; organic compounds containing sulphonic groups, or water-soluble salts thereof, e.g. polyanethol sulphonic acid salts, or m - amino - benzoyl - m - amino - p - methyl - benzoyl - 1 - naphthylamine - 4 - 6 - 8 trisulphonic acid carbamide; or the organ extracts known under the names Heparin, Hirudin and Novirudin.  These substances do not affect the cells and are either surface-tension depressants or prevent the coagulation of blood.  Antiseptic agents are also preferably added to the suspension, e.g. in amounts of the order of 0,1 to 0,2 per cent.  Suitable agents include camphoric acid, hexamethylene tetramine, hexamethylene tetramine triborate, anhydromethylene citric acid hexamethylene tetramine, salicylic acid phenyl ester, hexyl resorcin, and the methyl and ethyl esters of hydroxybenzoic acid.  The above substances may also be injected before the cell suspensions are prepared.  Such suspensions, e.g. of embryonal cells, cells of normal or diseased organs, or cancer cells may be treated for test purposes with sera, other cells, chemical reagents, ferments or hormones and the results observed by suitable methods.  According to examples: (1) a mixture of 0,25 c.c. secondary octyl alcohol, 0,75 c.c. absolute ethyl alcohol and 0,6 c.c. water is added to an agglutinated cell suspension in the proportion of 1 drop per c.c. of suspension.  After shaking, the agglomerations are broken up into single cells; (2) one drop of 1 per cent solution of Hirudin is added per c.c. of a cell suspension.  The cells remain singly in the suspension; (3) similarly one drop of 0,1 per cent aqueous solution of m-amino-benzoyl-m-amino - p - methyl - benzoyl - 1 - naphthylamine - 4-6-8-trisulphonic acid carbamide is added to each c.c. of a cell suspension; (4) a rabbit having a tumour is injected intravenously with 15 mgs. of the sodium salt of polyanethol sulphonic acid per kgm. living weight.  The tumour mass is isolated from the dead animal and worked up into a cell suspension which has little tendency to agglutinate.
INTRODUCTION: Presence of deep infiltrating bowel endometriosis (DE) is associated with occurrence of dyschezia and gastrointestinal symptoms. The degree of the disease, the lesion length, and the location, that is, lesion-to-anal-verge distance (LAVD) of DE, as well as the severity of the symptoms appear to be correlated. Nevertheless, it is not yet known to what extent the size and LAVD of bowel DE influence the severity of gastrointestinal symptoms. The present study aims to evaluate a possible correlation of lesion location (LAVD) and size (according to the #Enzian classification) with preoperative symptoms.
MATERIAL AND METHODS: In this prospective study, premenopausal patients with histologically confirmed DE undergoing modified limited nerve-vessel sparing rectal segmental bowel resection or full-thickness discoid resection were evaluated. Extent of endometriosis was defined according to the #Enzian classification during surgery. The primary outcome measure was the correlation between lesion size and location with the GI function impairment reflected by presurgical lower anterior resection syndrome (LARS) scores; the secondary outcome was differences in presurgical numeric rating scale pain scores of dyschezia, dyspareunia, and dysmenorrhea as well as the impact of concomitant DE of other locations on symptom intensity.
RESULTS: Of 162 consecutive patients, 151 were included in the final analysis. No significant correlation was observed between lesion size (#Enzian compartments C1/C2/C3) or LAVD and GI dysfunction reflected by LARS-like symptoms (p = 0.314 and p = 0.185, respectively) or pain symptoms (dyschezia, p = 0.440; dyspareunia, p = 0.136; and dysmenorrhea p = 0.221). Furthermore, no significant correlation was observed between lesion size and GI dysfunction when merging two severity grades (#Enzian compartments C1 plus C2 vs. C3; p = 0.611). In addition, LAVD did not affect the degree of dyschezia (p = 0.892), dyspareunia (p = 0.395), or dysmenorrhea (p = 0.705). Finally, the presence of concomitant DE lesions infiltrating the vagina/rectovaginal space (#Enzian compartment A) and/or sacrouterine ligaments/parametrium (#Enzian compartment B) did not alter the severity of preoperative dyschezia (p = 0.493) or dysmenorrhea (p = 0.128) but showed a trend toward affecting gastrointestinal function (p = 0.078) and was significantly associated with dyspareunia (p = 0.035).
CONCLUSIONS: In present study, we could not find a correlation between colorectal DE lesion size and location (LAVD) and gastrointestinal function impairment or intensity of dyschezia and dysmenorrhea. Additional involvement of vagina/rectovaginal space (#Enzian compartment A) and/or sacrouterine ligaments/parametrium (#Enzian compartment B) exerts a significant impact on the degree of dyspareunia in women with colorectal DE.
Participants will be instructed to consume study beverages to provide \>1.2 grams of protein per kilogram bodyweight and \>120% of total energy needs. Energy needs will be estimated by the Mifflin-St Jeor equation multiplied by an activity factor of 1.5. Study beverages will be a mix of meal replacement shakes e.g., Ensure (Abbott Laboratories, Chicago, IL, USA) products to accommodate protein and energy needs. Study beverages will be consumed every \~3 hours to induce a perpetually fed state. Feeding will occur during waking hours, typically between 7a-11p. Breath will be collected before, during and after the intervention.